Pacira BioSciences, Inc. (PCRX) · Nov 5, 2026 · Guidance
Guidance withdrawn
Pacira’s guidance withdrawal and canceled Q3 earnings release reflect the pending Viatris acquisition, not a new change in business performance.
Pacira is transitioning from a standalone EXPAREL-led pain company to a Viatris subsidiary. The company recently divested its iovera° device business and had been executing around EXPAREL growth, with 2026 guidance previously calling for $600–$620 million of EXPAREL sales and $735–$760 million of total revenue.
This filing removes the standalone-company scorecard while the acquisition proceeds. Pacira says it will not issue third-quarter results or hold a conference call, and is withdrawing its 2026 guidance during the proposed transaction. 〔0〕 〔1〕
The business signal is neutral because the change was already implied by the deal. Viatris announced the $36.50-per-share transaction on October 8, 2026, and the tender offer formally began on October 30, with expiration scheduled for November 16 unless extended. The filing confirms the expected transaction mechanics rather than revealing weaker demand, a new forecast cut, or a Q3 operating miss.
Bottom line: This is housekeeping around a pending acquisition, not a new verdict on Pacira’s operating performance. It matters mainly because investors will no longer receive a standalone Q3 update or updated 2026 outlook before the deal closes.||
Tender offer expires November 16, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!